IsoRay – Consensus Indicates Potential 233.8% Upside

Broker Ratings

IsoRay with ticker code (ISR) now have 3 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 3 and 1.6 calculating the mean target price we have 2.17. Now with the previous closing price of 0.65 this indicates there is a potential upside of 233.8%. The 50 day MA is 0.66 and the 200 day moving average is 0.84. The company has a market cap of $89m. Find out more information at:

Isoray, through its subsidiary, IsoRay Medical, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. Isoray was founded in 1998 and is headquartered in Richland, Washington.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen). Share on:

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index